News

A new clinical trial published on ClinicalTrials.gov is underway to better understand how indolent SM affects people and how it is managed. 

Nemolizumab, an anti-IL-31 receptor monoclonal antibody, may offer a novel way to treat severely itchy skin in indolent SM, study finds

Systemic mastocytosis (SM) is associated with more severe symptom flares than cutaneous mastocytosis (CM), according to a recent study.

A recent study identified previously unknown side effects from epinephrine, a treatment carried by many with SM.

Long-standing reference limits for serum tryptase in SM may need to be updated to better reflect age and sex differences, researchers say.

A new study provides a detailed snapshot of organ damage in patients with advanced SM at the time of enrollment in clinical trials.

Acupuncture may be a useful complementary therapy to help manage symptoms related to mast cell activation, but more research is needed.

A 13-year-old female was diagnosed with mast cell leukemia, a type of SM, and stage IV ovarian mixed germ cell tumor.

Indolent SM may cause the body to age faster than normal, according to a recent study published in the journal Innovation in Aging.

Cogent Biosciences submitted a New Drug Application to the FDA for bezuclastinib in non-advanced SM, with future submissions planned in 2026.